Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT05981274Recruiting
Bone health study of a long-acting factor VIII for hemophilia A
This study tests whether a long-acting factor VIII medicine (rFVIIIFc) helps protect the bones and joints of people with hemophilia A. If you have severe or moderate hemophilia with joint damage and are already on this treatment, you may be able to join.
Taipei, Neihu Dist.Ages Any age - NCT06206174RecruitingPhase 1/Phase 2
Study of TGRX-814 for blood cancers
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06345365RecruitingPhase 3
MA+AZA for Newly Diagnosed AML
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
Zhengzhou, HenanAges 18–75 - NCT04793919RecruitingPhase 2
Study of new treatment for youth with acute promyelocytic leukemia
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
BrusselsAges Up to 18 years - NCT06352216Recruiting
Joint inflammation in hemophilia A patients
This study looks at how many adults with moderate or severe hemophilia A have inflammation in their joints (synovitis). It aims to better understand joint health in people with hemophilia A, including those with inhibitors or joint replacements.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT03999723RecruitingPhase 2
Test azacitidine with vitamin C to improve DNA changes
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
AalborgAges 18 years+ - NCT05540834RecruitingPhase 2
Testing blood-clot guidance for ICU patients with severe lung failure
This Phase 2 trial tests whether using a blood test that shows clotting strength and “clot breakdown time” can help guide treatment for people in the ICU with acute respiratory failure from infection. If you qualify, the team will use these blood results to decide on clot-related therapy and compare outcomes to standard care.
Liverpool, New South WalesAges 18–75 - NCT05008744Recruiting
Laser treatment for twin-to-twin transfusion using one shared placenta
This study tests a laser procedure that seals abnormal blood vessel connections in identical twins sharing one placenta (twin-to-twin transfusion syndrome). The goal is to improve outcomes by stopping unbalanced blood flow between the twins.
Seattle, WashingtonAges Any age - NCT05678621RecruitingPhase 2/Phase 3
Testing stopping or extending immune treatment to prevent infections
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06376721RecruitingPhase 1/Phase 2
Linperlisib combo for advanced NK/T-cell lymphoma
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06375161RecruitingEarly Phase 1
CAR-T cells for relapsed B-cell cancers
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Shanghai, Shanghai MunicipalityAges 4 months–1.3 years - NCT06252298RecruitingPhase 1
Testing a new drug for CD38-positive blood cancers
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06378060RecruitingPhase 2
Modified Stem Cell Transplant for Severe Aplastic Anemia
This trial tests a new way to prepare the body for a donor stem cell transplant (allogeneic transplant) in people with severe aplastic anemia or other blood diseases. The goal is to make the transplant safer and more effective.
Kunming, YunnanAges 3–65 - NCT04565483RecruitingPhase 4
Test a blood-test signature to predict benralizumab benefit
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
Aix-en-ProvenceAges 18–75 - NCT06381817RecruitingPhase 3
Stem cell transplant comparison for T-cell leukemia
This study compares two types of stem cell transplants for adults with T-ALL: one using a half-matched donor alone, and one using a half-matched donor plus umbilical cord blood. The goal is to see which approach gives better results with fewer side effects.
Suzhou, JiangsuAges Any age - NCT06394011RecruitingPhase 2
New drug combo for intermediate/high risk AML
This trial tests a new combination of drugs (VA plus HAAG) for adults newly diagnosed with intermediate or high-risk AML. It aims to see if this combination is safe and effective for people who haven't had prior treatment.
Suzhou, JiangsuAges 18–65 - NCT06218628RecruitingPhase 1
Pacritinib and talazoparib for bone marrow cancers unresponsive to prior therapy
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT06149910Recruiting
Study of Treatment Plans for Newly Diagnosed Multiple Myeloma
This study looks at whether a new treatment plan (called a clinical pathway) helps doctors make better decisions for people just diagnosed with multiple myeloma. It will review medical records and may ask you to use a secure online platform to share your health information.
Seattle, WashingtonAges 18 years+ - NCT05502887Recruiting
Blood cancer registry study on blood vessel lining changes
This study enrolls adults with suspected or confirmed blood cancers to record information and look at changes in the blood vessel lining. Researchers hope this can help explain what happens over time and improve understanding of outcomes.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06002659RecruitingPhase 1/Phase 2
CAR T therapy targeting CD20 for B-cell lymphoma
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
StockholmAges Any age - NCT06405997Recruiting
Study of LAM: genes and symptoms
This study looks at the genes and physical traits of people with lymphangioleiomyomatosis (LAM), a rare lung disease that causes cysts. It aims to help better understand and treat LAM.
TaipeiAges 18 years+ - NCT04061512RecruitingPhase 2/Phase 3
Rituximab plus ibrutinib versus standard steroids plus rituximab
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
BathAges 18 years+ - NCT04201210RecruitingPhase 2
Stem cell transplant study for young people with severe sickle cell
This Phase 2 study tests a type of stem cell transplant that uses donor immune cells that have been specially “tweaked” to help treat sickle cell disease. It may help prevent serious sickle cell complications, but it requires careful matching and screening of organs and pregnancy status.
ViennaAges 2–35
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.